专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110319354A1 Combination Cancer Therapy with an AKT Inhibitor and Other Anticancer Agents 有权
标题翻译：联合癌症治疗与AKT抑制剂和其他抗癌剂
公开(公告)号：US20110319354A1
公开(公告)日：2011-12-29
申请号：US13254108
申请日：2010-02-23
申请人： Mark E. Layton , Hiroshi Hirai , Hidehito Kotani
发明人： Mark E. Layton , Hiroshi Hirai , Hidehito Kotani
IPC分类号： A61K31/704 , A61K31/7068 , A61P35/00 , A61K31/513 , A61K31/517 , A61K31/4375 , A61K31/4745
CPC分类号： A61K31/495 , A61K31/4196 , A61K31/50 , A61K2300/00
摘要： The invention relates to combination anticancer therapy with certain Akt inhibitor and other anticancer agents such as anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors.
摘要翻译：本发明涉及与某些Akt抑制剂和其它抗癌剂如抗癌抗代谢剂，抗癌抗生素，植物衍生抗癌剂，抗癌铂配位化合物，抗癌喜树碱衍生物和抗癌酪氨酸激酶抑制剂的组合抗癌治疗。

2. 发明授权

US08481503B2 Combination cancer therapy with an AKT inhibitor and other anticancer agents 有权
标题翻译：联合癌症治疗与AKT抑制剂和其他抗癌剂
公开(公告)号：US08481503B2
公开(公告)日：2013-07-09
申请号：US13254108
申请日：2010-02-23
申请人： Mark E. Layton , Hiroshi Hirai , Hidehito Kotani
发明人： Mark E. Layton , Hiroshi Hirai , Hidehito Kotani
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： A61K31/495 , A61K31/4196 , A61K31/50 , A61K2300/00
摘要： The invention relates to combination anticancer therapy with certain Akt inhibitor and other anticancer agents such as anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors.
摘要翻译：本发明涉及与某些Akt抑制剂和其他抗癌剂如抗癌抗代谢药，抗癌抗生素，植物衍生抗癌剂，抗癌铂配位化合物，抗癌喜树碱衍生物和抗癌酪氨酸激酶抑制剂的组合抗癌治疗。

3. 发明申请

US20120157342A1 PREDICTIVE BIOMARKERS USEFUL FOR CANCER THERAPY MEDIATED BY A WEE1 INHIBITOR 审中-公开
标题翻译：预防性生物标志物有用于癌症治疗由第一个抑制剂介导
公开(公告)号：US20120157342A1
公开(公告)日：2012-06-21
申请号：US13393915
申请日：2010-08-26
申请人： Shinji Mizuarai , Hiraku Itadani , Kazunori Yamanaka , Toshihide Nishibata , Tsuyoshi Arai , Hiroshi Hirai , Hidehito Kotani
发明人： Shinji Mizuarai , Hiraku Itadani , Kazunori Yamanaka , Toshihide Nishibata , Tsuyoshi Arai , Hiroshi Hirai , Hidehito Kotani
IPC分类号： C12Q1/68 , C40B30/04
CPC分类号： C12Q1/6883 , C12Q2600/118
摘要： The present invention provides the identification of biomarker gene sets whose expression levels are useful for predicting a patient's response to a therapeutically effective dose of a Wee1 inhibitor as well the ability to predict said response prior to dosing with the Wee1 inhibitor. Additional uses are also disclosed in the specification.
摘要翻译：本发明提供了生物标记基因组的鉴定，其表达水平可用于预测患者对治疗有效剂量的Wee1抑制剂的反应以及在施用Wee1抑制剂之前预测所述应答的能力。附加用途也在说明书中公开。

4. 发明申请

US20060019959A1 Novel quinoxalinone derivatives 失效
标题翻译：新型喹喔啉酮衍生物
公开(公告)号：US20060019959A1
公开(公告)日：2006-01-26
申请号：US10532677
申请日：2003-10-27
申请人： Hiroshi Hirai , Nobuhiko Kawanishi , Masaaki Hirose , Tetsuya Sugimoto , Kaori Kamijyo , Jun Shibata , Kouta Masutani
发明人： Hiroshi Hirai , Nobuhiko Kawanishi , Masaaki Hirose , Tetsuya Sugimoto , Kaori Kamijyo , Jun Shibata , Kouta Masutani
IPC分类号： A61K31/498 , C07D498/14 , C07D491/14
CPC分类号： C07D487/18 , A61K31/4995 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/55 , C07D498/18 , C07D498/22 , C07D515/18 , C07D515/22
摘要： A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn-1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B′1, B′2, . . . , B′n-1 and B′n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.
摘要翻译：式（I）的喹喔啉酮衍生物或其药学上可接受的盐或酯，其中： X是NH，S等; Y为O等; 该部分结构例如是以下公式：B 1，B 2，...。。。（其中n为4,5或6）各自独立地为CH，N等;其中n为4或5或6。 B'1，B'2，...，。。，其中n为4,5或6个，各自独立地为氢等;其中n为4或5或6。和R是氢，低级烷基等。

5. 发明授权

US06627914B1 Millimeter wave and far-infrared detector 有权
标题翻译：毫米波和远红外探测器
公开(公告)号：US06627914B1
公开(公告)日：2003-09-30
申请号：US09763603
申请日：2001-02-26
申请人： Susumu Komiyama , Astafiev Oleg , Antonov Vladimir , Hiroshi Hirai , Takeshi Kutsuwa
发明人： Susumu Komiyama , Astafiev Oleg , Antonov Vladimir , Hiroshi Hirai , Takeshi Kutsuwa
IPC分类号： H01L2906
CPC分类号： H01Q9/28 , B82Y10/00 , H01L31/02325 , H01L31/03046 , H01L31/0352 , H01L31/101
摘要： An MR/FIR light detector is disclosed herein that has extraordinarily high degree of sensitivity and a high speed of response. The detector includes an MR/FIR light introducing section (1) for guiding an incident MR/FIR light (2), a semiconductor substrate (14) formed with a single-electron transistor (14) for controlling electric current passing through a semiconductor quantum dot (12) formed therein, and a BOTAI antenna (6, 6a, 6b, 6c) for concentrating the MW/FIR light (2) into a small special zone of sub-micron size occupied by the semiconductor quantum dot (12) in the single-electron transistor (14). The quantum dot (12) forming a two-dimensional electron system absorbs the electromagnetic wave concentrated efficiently, and retains an excitation state created therein for 10 nanoseconds or more, thus permitting electrons of as many as one millions in number or more to be transferred with respect to a single photon absorbed.
摘要翻译：本文公开了具有非常高的灵敏度和高响应速度的MR / FIR光检测器。检测器包括用于引导入射MR / FIR光（2）的MR / FIR光导入部（1），形成有用于控制通过半导体量子的电流的单电子晶体管（14）的半导体衬底（14）形成在其中的点（12）和用于将MW / FIR光（2）聚集成由半导体量子点（12）占据的亚微米尺寸的小特殊区域的BOTAI天线（6,6a，6b，6c）单电子晶体管（14）。形成二维电子系统的量子点（12）吸收有效集中的电磁波，并且将其中产生的激发态保持10纳秒以上，从而允许多达一百万数以上的电子与尊重单个光子吸收。

6. 发明授权

US06180763B2 Cyclin D binding factor, and uses thereof 失效
标题翻译：细胞周期蛋白D结合因子及其用途
公开(公告)号：US06180763B2
公开(公告)日：2001-01-30
申请号：US08928941
申请日：1997-09-12
申请人： Charles J. Sherr , Hiroshi Hirai , Kazushi Inoue , Sara M. Bodner
发明人： Charles J. Sherr , Hiroshi Hirai , Kazushi Inoue , Sara M. Bodner
IPC分类号： C07K122
CPC分类号： C07K14/4705 , A01K2217/05 , A01K2217/075 , C07K2319/00
摘要： The invention discloses a direct interaction between D-type cyclins and a novel myb-like transcription factor, DMP1, which specifically interacts with cyclin D2. The present invention also provides evidence that D-type cyclins regulate gene expression in an RB-independent manner. Also included is DMP1, the transcription factor composed of a central DNA-binding domain containing three atypical myb repeats flanked by highly acidic segments located at its amino- and carboxyterminal ends. The invention includes amino acid sequences coding for DMP1, and DNA and RNA nucleotide sequences that encode the amino acid sequences. A use of DMP1 as a transcription factor is disclosed due to its specificity in binding to oligonucleotides containing the nonamer consensus sequence CCCG(G/T)ATGT. In this aspect of the invention, DMP1 when transfected into mammalian cells, activates the transcription of a reporter gene driven by a minimal promoter containing concatamerized DMP1 binding sites.
摘要翻译：本发明公开了D型细胞周期蛋白与与细胞周期蛋白D2特异性相互作用的新型myb样转录因子DMP1之间的直接相互作用。本发明还提供了D型细胞周期蛋白以不依赖RB的方式调节基因表达的证据。还包括DMP1，转录因子由包含三个非典型myb重复的中心DNA结合结构域组成，其侧翼为位于其氨基末端和羧基末端的高度酸性的片段。本发明包括编码DMP1的氨基酸序列，以及编码氨基酸序列的DNA和RNA核苷酸序列。公开了DMP1作为转录因子的用途，因为它在与含有非标记共有序列CCCG（G / T）ATGT的寡核苷酸的结合中具有特异性。在本发明的这个方面，当转染到哺乳动物细胞中时，DMP1激活由含有连接的DMP1结合位点的最小启动子驱动的报道基因的转录。

7. 发明申请

US20100063024A1 Dihydropyrazolopyrimidinone Derivatives 有权
标题翻译：二氢吡唑并嘧啶酮衍生物
公开(公告)号：US20100063024A1
公开(公告)日：2010-03-11
申请号：US12226707
申请日：2007-04-25
申请人： Toshihiro Sakamoto , Takeshi Sagara , Sachie Otsuki , Satoshi Sunami , Kenji Niiyama , Fuyuki Yamamoto , Takashi Yoshizumi , Hidetomo Furuyama , Yasuhiro Goto , Makoto Bamba , Keiji Takahashi , Hiroshi Hirai , Toshihide Nishibata
发明人： Toshihiro Sakamoto , Takeshi Sagara , Sachie Otsuki , Satoshi Sunami , Kenji Niiyama , Fuyuki Yamamoto , Takashi Yoshizumi , Hidetomo Furuyama , Yasuhiro Goto , Makoto Bamba , Keiji Takahashi , Hiroshi Hirai , Toshihide Nishibata
IPC分类号： A61K31/397 , C07D487/04 , C07D413/14 , C07D417/14 , A61K31/496 , A61K31/5377 , A61K31/541 , A61P35/00
CPC分类号： C07D487/04 , A61K31/4162 , A61K31/519
摘要： The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc.The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.
摘要翻译：本发明涉及通式（I）的化合物：其中Ar1是任选取代的芳基或杂芳基; R 1是任选取代的低级烷基，低级烯基，低级炔基或环低级烷基，或者是任选具有取代基的芳基，芳烷基或杂芳基; R2是氢原子，低级烷基，低级烯基或低级炔基，或者是任选具有取代基的芳基，芳烷基或杂芳基; R3是氢原子或低级烷基; R4是氢原子，卤素原子，羟基，低级烷基或-N（R1k）R1m基团; T和U是氮原子或次甲基等。本发明的化合物具有优异的韦尔激酶抑制作用，因此可用于药物领域，特别是治疗各种癌症。

8. 发明授权

US07388010B2 Quinoxalinone derivatives 失效
标题翻译：喹喔啉酮衍生物
公开(公告)号：US07388010B2
公开(公告)日：2008-06-17
申请号：US10532677
申请日：2003-10-27
申请人： Hiroshi Hirai , Nobuhiko Kawanishi , Masaaki Hirose , Tetsuya Sugimoto , Kaori Kamijyo , Jun Shibata , Kouta Masutani
发明人： Hiroshi Hirai , Nobuhiko Kawanishi , Masaaki Hirose , Tetsuya Sugimoto , Kaori Kamijyo , Jun Shibata , Kouta Masutani
IPC分类号： A61K31/498 , A61P35/00 , C07D487/00
CPC分类号： C07D487/18 , A61K31/4995 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/55 , C07D498/18 , C07D498/22 , C07D515/18 , C07D515/22
摘要： A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn−1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B′1, B′2, . . . , B′n−1 and B′n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.
摘要翻译：式（I）的喹喔啉酮衍生物或其药学上可接受的盐或酯，其中： X是NH，S等; Y为O等; 该部分结构例如是以下公式：B 1，B 2，...。。。（其中n为4,5或6）各自独立地为CH，N等;其中n为4或5或6。 B'1，B'2，...，。。，其中n为4,5或6个，各自独立地为氢等;其中n为4或5或6。和R是氢，低级烷基等。

9. 发明授权

US06673902B2 Cyclin D binding factor, and uses thereof 失效
标题翻译：细胞周期蛋白D结合因子及其用途
公开(公告)号：US06673902B2
公开(公告)日：2004-01-06
申请号：US09892398
申请日：2001-06-27
申请人： Charles J. Sherr , Hiroshi Hirai , Sara M. Bodner , Kazushi Inoue
发明人： Charles J. Sherr , Hiroshi Hirai , Sara M. Bodner , Kazushi Inoue
IPC分类号： C07K1600
CPC分类号： C07K14/4705 , A01K2217/05 , A01K2217/075 , C07K2319/00
摘要： The invention discloses a direct interaction between D-type cyclins and a novel myb-like transcription factor, DMP1, which specifically interacts with cyclin D2. The present invention also provides evidence that D-type cyclins regulate gene expression in an RB-independent manner. Also included is DMP1, the transcription factor composed of a central DNA-binding domain containing three atypical myb repeats flanked by highly acidic segments located at its amino- and carboxyterminal ends. The invention includes amino acid sequences coding for DMP1, and DNA and RNA nucleotide sequences that encode the amino acid sequences. A use of DMP1 as a transcription factor is disclosed due to its specificity in binding to oligonucleotides containing the nonamer consensus sequence CCCG(G/T)ATGT. In this aspect of the invention, DMP1 when transfected into mammalian cells, activates the transcription of a reporter gene driven by a minimal promoter containing concatamerized DMP1 binding sites.
摘要翻译：本发明公开了D型细胞周期蛋白与与细胞周期蛋白D2特异性相互作用的新型myb样转录因子DMP1之间的直接相互作用。本发明还提供了D型细胞周期蛋白以不依赖RB的方式调节基因表达的证据。还包括DMP1，转录因子由包含三个非典型myb重复的中心DNA结合结构域组成，其侧翼为位于其氨基末端和羧基末端的高度酸性的片段。本发明包括编码DMP1的氨基酸序列，以及编码氨基酸序列的DNA和RNA核苷酸序列。公开了DMP1作为转录因子的用途，因为它在与含有非标记共有序列CCCG（G / T）ATGT的寡核苷酸的结合中具有特异性。在本发明的这个方面，当转染到哺乳动物细胞中时，DMP1激活由含有连接的DMP1结合位点的最小启动子驱动的报道基因的转录。

10. 发明授权

US07834019B2 Substituted pyrazolo[3,4-d]pyrimidinone derivatives 有权
标题翻译：取代的吡唑并[3,4-d]嘧啶酮衍生物
公开(公告)号：US07834019B2
公开(公告)日：2010-11-16
申请号：US11789548
申请日：2007-04-25
申请人： Takeshi Sagara , Sachie Otsuki , Satoshi Sunami , Toshihiro Sakamoto , Kenji Niiyama , Fuyuki Yamamoto , Takashi Yoshizumi , Hidetomo Furuyama , Yasuhiro Goto , Makoto Bamba , Keiji Takahashi , Hiroshi Hirai , Toshihide Nishibata
发明人： Takeshi Sagara , Sachie Otsuki , Satoshi Sunami , Toshihiro Sakamoto , Kenji Niiyama , Fuyuki Yamamoto , Takashi Yoshizumi , Hidetomo Furuyama , Yasuhiro Goto , Makoto Bamba , Keiji Takahashi , Hiroshi Hirai , Toshihide Nishibata
IPC分类号： A61K31/519 , A61K31/497 , C07D487/04 , A61P35/00
CPC分类号： C07D487/04 , A61K31/4162 , A61K31/519
摘要： The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.
摘要翻译：本发明涉及通式（I）的化合物：其中Ar1是任选取代的芳基或杂芳基; R 1是任选取代的低级烷基，低级烯基，低级炔基或环低级烷基，或者是任选具有取代基的芳基，芳烷基或杂芳基; R2是氢原子，低级烷基，低级烯基或低级炔基，或者是任选具有取代基的芳基，芳烷基或杂芳基; R3是氢原子或低级烷基; R4是氢原子，卤素原子，羟基，低级烷基或-N（R1k）R1m基团; T和U是氮原子或次甲基等。本发明的化合物具有优异的韦尔激酶抑制作用，因此可用于药物领域，特别是治疗各种癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式